Effect of Early Use of Caffeine Citrate in Preterm Neonates
Palabras clave
Abstracto
Descripción
Caffeine citrate is one of the most widely used drugs in neonatal intensive care units. It is a respiratory stimulant which has well established therapeutic effects in apnea and facilitation of extubation. Caffeine is an adenosine antagonist ; it blocks selectively A2 receptors and non selective blocks A1 receptors. Its effects include improved lung compliance, minute ventilation, respiratory muscle contractility, increased sensitivity to carbon dioxide, enhanced catecholamine activity and decreased airway resistance
Early caffeine therapy was associated with a shorter duration of respiratory support and reduction in bronchopulmonary dysplasia , cerebral palsy, patent ductus arteriosis ligation, intracranial hemorrhage, apnea and death
Despite its widespread use, information regarding optimal time to initiate therapy and appropriate time to discontinue therapy is limited. Recent studies have indicated that early initiation of caffeine therapy is associated with improved neonatal outcomes
Little is known about the early use of caffeine citrate in preterm neonates. The investigators aim to explore the effectiveness of its very early use in reducing the duration of respiratory support.
fechas
| Verificado por última vez: | 05/31/2019 |
| Primero enviado: | 06/21/2019 |
| Inscripción estimada enviada: | 06/25/2019 |
| Publicado por primera vez: | 06/27/2019 |
| Última actualización enviada: | 06/27/2019 |
| Última actualización publicada: | 07/01/2019 |
| Fecha de inicio real del estudio: | 04/04/2019 |
| Fecha estimada de finalización primaria: | 05/04/2019 |
| Fecha estimada de finalización del estudio: | 06/09/2019 |
Condición o enfermedad
Intervención / tratamiento
Drug: Caffeine Citrate
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: early caffeine citrate group preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support | |
| Active Comparator: late caffeine citrate group preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support |
Criterio de elegibilidad
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: 1. Preterm neonates ≤ 33 weeks gestational age. 2. Preterm neonates who need respiratory support (either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation). Exclusion Criteria: 1. Neonate>33 wks gestational age. 2. Neonates on room air. 3. Neonates with major congenital or cardiac anomalies |
Salir
Medidas de resultado primarias
1. duration of respiratory support in preterm neonates receiving early caffeine citrate [throughout admission in neonatal intensive care unit average of 4 weeks (from the beginning of hospital admission till discharge) average of]
